Skip to main content

Emergent BioSolutions to Manufacture Another COVID-19 Vaccine Candidate

Emergent BioSolutions Inc. has received $135M in funding from Johnson & Johnson that will support large-scale manufacturing of J&J’s lead COVID-19 vaccine candidate at their Baltimore City-based manufacturing facility. "Emergent could make up to 300 million doses to advance the vaccine candidate," said Syed Husain, senior vice president, according to the

Read More

Subscribe to our mailing list: